Immunome, Inc. (IMNM)
18.70
-0.37
(-1.94%)
USD |
NASDAQ |
Nov 12, 16:00
18.71
+0.01
(+0.05%)
After-Hours: 20:00
Immunome Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2025 | 82.07% |
| March 31, 2025 | 75.19% |
| December 31, 2024 | 78.27% |
| September 30, 2024 | 80.38% |
| June 30, 2024 | 71.53% |
| Date | Value |
|---|---|
| March 31, 2024 | 74.44% |
| December 31, 2023 | 93.28% |
| September 30, 2023 | 95.34% |
| June 30, 2023 | 96.32% |
| March 31, 2023 | 93.74% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 91.15% |
| Revolution Medicines, Inc. | 97.26% |
| Erasca, Inc. | -- |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | 39.18% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -57.30% |
| Return on Assets | -52.87% |
| Return on Invested Capital | -56.67% |
| Return on Net Operating Assets | -1.50K% |